Vestal Point Capital, LP Savara Inc Transaction History
Vestal Point Capital, LP
- $1.34 Trillion
- Q2 2024
A detailed history of Vestal Point Capital, LP transactions in Savara Inc stock. As of the latest transaction made, Vestal Point Capital, LP holds 6,490,000 shares of SVRA stock, worth $23.4 Million. This represents 1.95% of its overall portfolio holdings.
Number of Shares
6,490,000Holding current value
$23.4 Million% of portfolio
1.95%Shares
1 transactions
Others Institutions Holding SVRA
# of Institutions
144Shares Held
147MCall Options Held
242KPut Options Held
797K-
Nea Management Company, LLC Timonium, MD24.5MShares$88.1 Million9.31% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA14.6MShares$52.4 Million12.01% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$44.5 Million7.46% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.16MShares$29.4 Million1.94% of portfolio
-
Black Rock Inc. New York, NY8.03MShares$28.9 Million0.0% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $411M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.